Drugs / AL8326
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07132957 | Feb → May 2025 | small cell lung carcinoma | Advenchen Laboratories, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05486598 | Jun → Dec 2022 | — | Advenchen Laboratories, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT06794957 | May 2022 → Dec 2027 expected | non-small cell lung carcinoma | Advenchen Laboratories, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04890587 | Aug 2017 → Dec 2023 | cancer | Advenchen Laboratories, LLC | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07392736 | Oct 2021 → Nov 2029 expected | neoplasm | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04890795 | Oct 2020 → Sep 2021 | small cell lung carcinoma | Advenchen Laboratories, LLC | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06247605 | Oct 2023 → Jul 2028 expected | small cell lung carcinoma | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL8326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04890795 ↗ |
| Route | Oral | “administered orally” NCT04890587 ↗ |